Formulation Matters: Nutrient Availability and Label Accuracy of Supplements for Age-Related Macular Degeneration.
Researchers
Alexandra Sheila P M de Koning-Backus, Jessica C Kiefte-de Jong, Tos J M Berendschot, Magda A Smoor, Caroline C W Klaver
Abstract
AREDS2-based supplements can reduce progression to advanced AMD, but commercially available supplements can differ in characteristics. The aim of this study was to compare two AMD supplements with different coatings for their effects on serum lutein and zeaxanthin (L&Z) levels, and to analyze commercially available supplements for label accuracy and levels of AREDS2-relevant nutrients. In a randomized, open-label trial, 11 healthy adults aged 25 to 64 years received either AREDS2 formulation delivered in a softgel (B1) or a L&Z-containing herbal-coated tablet (B2) for four weeks, followed by crossover to the alternate intervention. Serum L&Z levels were measured at baseline and after each intervention. Twenty-three commercially available AMD supplements were analyzed for their content of L&Z, vitamins C and E, zinc, copper, and omega-3 fatty acids. Measured values were compared with product label claims and AREDS2 reference standards. B1 significantly increased serum levels of lutein (0.13 → 0.31 µmol/L, P = 0.003) and zeaxanthin (0.08 → 0.11 µmol/L, P = 0.003), whereas B2 produced no measurable change. Commercial supplement analysis revealed substantial variability: lutein ranged from 76%-207% and zeaxanthin from 59%-326% of declared amounts. Only four of 23 products matched AREDS2 formulation; several were overfortified, and some lacked detectable nutrient levels. This study demonstrates that dosage form significantly influences nutrient-availability after intake of AMD-supplements, and that commercial products frequently deviate from their labeled nutrient content. These findings are relevant for AMD management and underscore the need for standardized testing and stricter quality control.Source: PubMed (PMID: 43043343)View Original on PubMed